Seller record · Telehealth service
PrideRx
Fails 1 of 8 criteria. S5, analytical documentation: No certificate, lot number or purity document appears on the weight-loss pages, the answers or the legal pages.
At a glance
PrideRxTelehealth service
- Price
- Membership $25 the first month, then $99 a month; Zepbound from $299 a month and the Wegovy pill and Foundayo from $149, billed separately
- Sells
- Zepbound KwikPen, Wegovy pill, Foundayo
- FDA letters
- None on file
Telehealth service. Passes 7 of 8 criteria. Recorded against Standard v1.1.
A telehealth service that prescribes only brand GLP-1 medications, Zepbound, the Wegovy pill and Foundayo, for a monthly membership fee, with the medication billed separately by the manufacturers' own pharmacy programs, alongside sexual health, PrEP and hair loss care. Care starts with a short set of health questions.
Operating entity PrideRx LLC
Dispositions
| Code | Criterion | Disposition | Where it appears |
|---|---|---|---|
| S1 | Prescriber requirement | PASS | PrideRx's Zepbound page; PrideRx's FAQ |
| S2 | Prescription gating | PASS | PrideRx's Zepbound page; PrideRx's Wegovy page; PrideRx's Foundayo page |
| S3 | Pharmacy identification | PASS | PrideRx's FAQ; PrideRx's weight loss page |
| S4 | Compounding disclosure | PASS | PrideRx's weight loss page |
| S5 | Analytical documentation | FAIL | PrideRx's weight loss page; PrideRx's FAQ; PrideRx's terms |
| S6 | Business address | PASS | PrideRx's returns refund policy; PrideRx's contact page; PrideRx's terms |
| S7 | Price disclosure | PASS | PrideRx's Zepbound page; PrideRx's Wegovy page; PrideRx's Foundayo page; PrideRx's weight loss page |
| S8 | Enforcement status | PASS | FDA warning-letter index |
Evidence, criterion by criterion
The evidence behind each disposition in the table above, where it appears, and its date.
Products shown on the seller's own pages at the recorded date: Zepbound KwikPen, Wegovy pill, Foundayo.
Other sellers of the same products
A warning letter to a pharmacy this seller names
FDA warning letter 663403, issued September 2023, to Curexa – East, LLC dba Curexa“During the inspection, the investigators noted serious deficiencies in your practices for producing drug products, which put patients at risk.”
The letter is addressed to the pharmacy, not to PrideRx, and changes no disposition on this record.
Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.